Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 156 participants.

Also called NCT06750341

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 156 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06750341
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06750341. Randomized; quadruple masking; primary purpose treatment. Start 2025-02 (anticipated); primary completion 2026-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol
Condition
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Intervention (Drug)
QLC7401
Intervention (Drug)
Placebo
Lead sponsor
Qilu Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06750341
Content hash
36c95ec510bd085cfa8f709e0d4d6324c0edc0d691bdebef980c30ebcde121ad